Hyloris Pharmaceuticals Announces Warrant Plan Expiry and Share Capital Details

Hyloris Pharmaceuticals SA ( (DE:52U) ) has issued an update.

Hyloris Pharmaceuticals SA announced the expiry of a warrant plan for its employees and managers, with the total share capital amounting to EUR 140,001.87. The company disclosed that there are 309,313 subscription rights granted, which will lead to the issuance of ordinary shares. This announcement reflects the company’s current financial structure and potential equity movements, which may have implications on its market positioning and investor relations.

More about Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA is a specialty biopharma company based in Liège, Belgium, focused on innovating, reinventing, and optimizing existing medications. The company leverages existing regulatory pathways like the FDA’s 505(b)2 to reduce development timelines and costs, and has a broad portfolio of reformulated and repurposed medicines, including Sotalol IV and Maxigesic® IV. Hyloris also develops high barrier generic products.

YTD Price Performance: -20.73%

Average Trading Volume: 917

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €173M

See more data about 52U stock on TipRanks’ Stock Analysis page.